High-risk mucosal human papillomaviruses (HPV), mainly HPV16 and HPV18, are implicated in cervical carcinogenesis. HPV16 E6 oncoprotein binds and often targets for degradation numerous cell proteins, including the tumor suppressor p53 and several PDZ domain proteins. Here, we show that a single-point mutation, F47R, is sufficient to convert the HPV16 E6 oncoprotein into a suppressor of HPV-positive HeLa cervical cancer cells proliferation. The E6 F47R mutant is defective for polyubiquitination and subsequent degradation of p53. When expressed in HPV-positive cervical cancer cells, E6 F47R acts as a dominant negative mutant by counteracting the p53 degradation activity of endogenous E6 and restoring high p53 protein levels. Moreover, the prolonged expression of E6 F47R leads to suppression of HeLa cells proliferation through the induction of premature senescence. This phenotype is independent on the PDZ-binding activity of E6. F47R-senescent HeLa cells exhibit a sustained expression of p53, hMDM2 and p21 CIP proteins and a reduced expression of endogenous HPV18 E6 protein. Finally, small interfering RNAs directed against p53 counteract the effect of E6 F47R expression, indicating that E6 F47R-induced cellular senescence is strongly dependent on p53 signaling pathway.
Introduction
Infection with high-risk human papillomaviruses (HPV), mainly HPV16 and HPV18, has been shown as the major cause of cervical carcinoma (zur Hausen, 1996) . High-risk HPV E6 and E7 oncoproteins target cellular regulators for degradation, respectively p53 and pRB proteins, and are essential for malignant transformation and for the maintenance of the transformed phenotype (Vousden, 1993) .
HPV16 E6 protein is a multifunctional protein of 19 kDa composed of two zinc-binding domains (Lipari et al., 2001; Nomine´et al., 2003 Nomine´et al., , 2006 . E6 elicits the polyubiquitination of p53 and its degradation by the 26S proteasome (Scheffner et al., 1990) . This effect has been related to the formation of a trimeric complex involving E6, p53 and the cellular ubiquitin ligase E6AP (Huibregtse et al., 1991) . At its COOH extremity, E6 contains a PDZ-binding motif allowing the interaction with PDZ-containing proteins involved in cell adhesion, proliferation and polarity, such as hDLG, hMAGI-1, hScrib, MUPP1 . Moreover, E6 activates the telomerase activity through transactivation of the hTERT gene (Veldman et al., 2001) .
Numerous studies have shown that E6 is a promising target to inhibit cellular proliferation of cervical cancer cells. The inhibition of E6 was obtained at the mRNA level by RNA interference (Butz et al., 2003) or at the protein level by transduced full-length anti-E6 antibody (Courtete et al., 2007) or recombinant antibody fragments (Griffin et al., 2006; Lagrange et al., 2007) . In these studies, selective E6 inhibition was found to induce cell growth arrest accompanied in some cases by apoptosis. By contrast, senescence was observed upon combined repression of both E6 and E7 expression mediated either by RNA interference (Hall and Alexander, 2003) or by ectopic expression of the bovine papillomavirus E2 protein, a transcriptional repressor of E6/E7 promoter (Wells et al., 2000; Lee et al., 2002; Horner et al., 2004) .
We recently identified a p53 degradation-defective mutant of HPV16 E6 (E6 F47R 6C6S), which restored p53 protein in HeLa cells (Nomine´et al., 2006) . In our earlier study, we had introduced the F47R mutation in the context of a biochemically stabilized 16E6 mutant, namely E6 6C6S. In this study, we analyse the F47R mutation in the context of wild-type 16E6 and show that this single-point mutant restores high levels of p53 protein in HPV-positive cervical cancer cells leading to the induction of a senescent phenotype in HeLa cells dependent on the p53 signaling pathway.
Results

E6 F47R has a dominant negative phenotype regarding p53 degradation in cervical carcinoma cells
We previously identified a mutant of HPV16 E6 protein (F47R 6C6S) that was defective in p53 degradation and induced high p53 levels when overexpressed in HPV18-positive HeLa cells (Nomine´et al., 2006) . This mutant was originally constructed into the context of six nonconserved cystein residues mutated to serine residues to reduce aggregation during the production of recombinant 16E6 protein (Nomine´et al., 2001a, b) . In this study, we examined the biochemical and biological properties of the single-point mutant F47R in the context of the wild-type protein. When HeLa cells were transfected with plasmids encoding E6 wild type and E6 F47R, the E6 F47R mutant was found to increase p53 protein level dramatically (Figures 1a and b) . E6 F47R was also found to restore p53 expression in HPV16-positive cells CaSki (Figures 1a and b) and SiHa ( Figure 1a) . Remarkably, treatment with the proteasome inhibitor MG132 strongly increased the steady-state level of p53 in HeLa cells transfected either with control plasmid or 16E6, whereas it did not alter the high level of p53 in HeLa cells transfected with F47R (Figure 1c ). This indicated that F47R expression directly inhibited endogenous E6-mediated p53 degradation in HeLa cells. Therefore, the E6 F47R mutant presented a dominant negative mutant phenotype regarding p53 degradation in HPV-positive cancer cells.
E6 F47R associates with E6AP and p53 into complexes deficient for p53 polyubiquitination and subsequent degradation Next, we investigated the ability of E6 F47R to induce p53 degradation in vitro and in HPV-negative cells. E6, E6 F47R and p53 were produced and labeled with 35 S in rabbit reticulocyte lysates. In this assay, the E6 F47R protein did not induce the degradation of the p53 protein, in contrast to wild-type E6 (Figure 2a) . We also examined the polyubiquitination of p53 in vitro as described previously (Liu et al., 1999) . In vitro-translated p53 was incubated with E6 or E6 F47R in the presence of ATP-gS to avoid degradation by proteasome. Wildtype E6 induced the ubiquitination of p53 compared with water-primed lysate, whereas F47R failed to induce p53 ubiquitination (Figure 2b ). The p53-null lung carcinoma cells H1299 were co-transfected with plasmids encoding wild-type p53 and E6 (wild type or F47R) (Figure 2c ). Whereas the expression of p53 protein strongly decreased upon co-expression with wild-type E6, it was not altered upon co-expression with E6 F47R. Therefore, the E6 F47R mutant is defective for degrading wild-type p53 in vitro and in vivo. Interestingly, we noticed that the steady-state level of E6 F47R protein was generally higher than the wild-type E6 level. It might be possible that the F47R mutation alters the turnover of E6 protein, which is known as a short-lived protein (Stewart et al., 2004) .
As the E6 F47R restores high p53 protein level in HPV16-and HPV18-positive cells, we investigated the ability of this mutant to inhibit E6 in vitro. For this purpose, 16E6 wild type and E6 F47R were expressed in Escherichia coli as C-terminal fusions to the maltosebinding protein (MBP) and affinity purified. The MBP tag is essential to preserve the solubility of wildtype E6, which otherwise precipitates very rapidly (Nomine´et al., 2001a, b) . By contrast to MBP-E6, MBP-E6 F47R inhibited the ability of 16E6 to induce the degradation of p53 in rabbit reticulocytes lysates (Figure 2d) . Therefore, the E6 F47R mutant also acts as a dominant negative mutant in the in vitro degradation assay.
Finally, we analysed the formation of triple complex between E6/E6AP/p53 by using in vivo GST pulldown (Nomine´et al., 2006) . E6 wild-type or E6 F47R were coexpressed with GST-E6AP C843A, a E6AP mutant that binds to E6 but is inactive as an ubiquitin ligase (Talis et al., 1998) in cervical cancer C33A cells that contain high level of transactivation-defective p53 mutant. The complex was purified on glutathione-agarose beads and subjected to western blotting analysis (Figure 2e , see also Figure 2f for controls). E6 F47R interacted with GST-E6AP C843A and recruited p53 similarly to the E6 wild-type protein. This contrasts with the E6 F47R 6C6S mutant, which is strongly impaired for triple complex formation (Nomine´et al., 2006) . This suggests that whereas the 6C6S mutations are useful for biochemical solubilization of recombinant E6, they are not neutral when combined with the additional F47R mutation. In conclusion, E6 F47R retains the capacity to form the E6/E6AP/p53 triple complex, but this complex is deficient for p53 polyubiquitination and subsequent degradation.
E6 F47R inhibits proliferation of HeLa cells
We next addressed the fate of cervical cancer cells presenting high p53 protein levels restored by prolonged expression of dominant negative E6 mutant. As E6 binds to other tumor suppressor products, such as hDLG, hMAGI-1 or hScrib through its PDZ-binding motif, a double E6 mutant combining F47R mutation with a deletion of the last seven residues corresponding to PDZ-binding motif was also constructed. Plasmids encoding E6, F47R or F47RDPDZ were transfected into HPV-positive HeLa cells and into the HPV-negative cancer cells C33A and H1299. Twenty-four hours after transfection, the expression of E6 proteins was verified by western blotting (Figure 3a ). Transfected cells were selected for puromycin resistance during 2-3 weeks and the colonies were stained with crystal violet (Figure 3b ). In HPV18-positive HeLa cells, expression of 16E6 did not influence colony formation, whereas the expression of E6 F47R and E6 F47RDPDZ resulted in a dramatic inhibition of colony formation. By contrast, E6 F47R and E6 F47RDPDZ constructs did not influence colony formation of HPV-negative C33A cells and H1299 cells as compared with wild-type E6 construct. We observed that in all tested cell lines, the E6 expression resulted in fewer colonies than transfection with empty plasmid, indicating that overexpression of this oncoprotein might induce some cytotoxicity. This is not surprising considering that E6 interacts with at least 40 cellular proteins related to the control of proliferation, cell death and cell adhesion. In conclusion, these data indicated that E6 F47R expression selectively induced a cell growth suppression phenotype in HPV-positive HeLa cells. plasmids pEGFP-C3, p513-E6 and p513-E6 F47R, whereas CaSki and SiHa cells were transfected with plasmids p513-E6 and p513-E6 F47R. Twenty-four hours later, E6 and p53 expression was analysed by immunofluorescence as described (Nomine´et al., 2006) . (b) HeLa and CaSki were transfected with empty vector or pNKA-E6, pNKA-E6 F47R. Twenty-four hours after transfection, extracted proteins were separated on SDS-12% polyacrylamide gel and analysed by western blotting using monoclonal anti-p53 antibody, anti-actin antibody and monoclonal anti-16E6 antibody. (c) HeLa cells were transfected with empty vector, pNKA-E6, pNKA-E6 F47R. Twenty-four hours after transfection, cells were treated in the presence or in the absence of proteasome inhibitor MG132 (10 mM) for 4 h. Extracted proteins were separated on SDS-12% polyacrylamide gel and analysed by western blotting using monoclonal anti-p53 antibody, anti-actin antibody and monoclonal anti-16E6 antibody.
HPV16 E6 mutant and cellular senescence T Ristriani et al E6 F47R induces premature cellular senescence of HeLa cells To investigate the pathway leading to cell growth suppression, we analysed by western blotting the PARP1 protein, a 113 kDa enzyme cleaved into a 85 kDa fragment by caspases at early stage of apoptosis ( Figure 4A ). We did not observe any cleavage of PARP1 polypeptide in HeLa-expressing E6 mutants in contrast to HeLa cells treated with staurosporine, a drug that triggers apoptosis (Bernard et al., 2003) . Therefore, cell growth suppression induced by E6 mutants was not driven by induction of caspase-dependent apoptosis. After 6 days of selection, HeLa cells-expressing E6 mutants stopped to divide and changed cellular morphology (with enlarged flat cytoplasm and long cytoplasmic projections). These cells exhibited a positive staining for acidic SA-b-galactosidase activity, known as a marker of senescence (Dimri et al., 1995;  Figure 4B ). This indicates that E6 F47R and E6 F47RDPDZ induced premature senescence of HeLa cells. S Met in rabbit reticulocytes lysates, were incubated at 25 1C for 2 h. Samples, taken at time 0 or after 2 h of incubation, were loaded on SDS-12% polyacrylamide gel. Gel was exposed to autoradiography. (b) Labeled in vitro-translated p53 was incubated with E6 or F47R at 25 1C in the presence of ATP-gS. After incubation, the mixture was immunoprecipitated with monoclonal anti-p53 antibody and collected on protein G sepharose and boiled, and then the supernatant was reimmunoprecipitated with antiubiquitin antiserum, adsorbed on protein G sepharose and run on an SDS-12% polyacrylamide gel. (c) H1299 cells (35-mm diameter dishes) were co-transfected with pcDNA-p53 (0.5 mg) or empty vector pcDNA and pXJ-E6 (1.5 mg), pXJ-E6 F47R or pXJ empty vector. Twenty-four hours after transfection, extracted proteins were separated on SDS-12% polyacrylamide gel and analysed by western blotting using monoclonal anti-p53 antibody, anti-actin antibody and monoclonal anti-16E6 antibody. . After 2 h of incubation, samples were loaded on an SDS-12% polyacrylamide gel. Gel was exposed to autoradiography. (e) C33A cells were co-transfected with pBC-E6AP C843A, (encoding GST-E6AP C843A) and p513, p513-E6 wt or p513-E6 F47R. Thirty hours later, cell lysates were incubated with glutathione beads at 4 1C. Proteins corresponding to 10% of the input and proteins retained on beads were analysed by western blotting with anti-16E6, anti-p53, anti-E6AP and anti-GST antibodies. (f) Negative control experiments using pBC vector encoding for GST alone.
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Sustained activation of p53 and decrease of 18E6 protein levels in senescent HeLa cells Stabilized p53 is responsible for the transcriptional activation of a series of p53-responsive genes involved in cell cycle control, apoptosis and senescence, including p21 CIP and hMDM2. Two days after transfection of HeLa cells by a plasmid encoding E6 F47R, we observed that p53 protein levels were upregulated (Figure 5a ). hMDM2 protein and p21 CIP protein levels were also increased. In contrast, the levels of endogenous 18E6 and 18E7 proteins remained unchanged. Moreover, when HeLa cells were co-transfected with plasmid encoding E6 wild-type or mutant and a plasmid containing the p21 CIP -luciferase reporter gene (Figure 5b ), luciferase activity was specifically enhanced in cells expressing E6 F47R, indicating that stabilized p53 activated the transcription of the p21 CIP gene. At day 6 post-transfection when the senescent phenotype was observed, the levels of p53, p21 CIP and hMDM2 proteins remained upregulated in senescent HeLa cells (Figure 5c ). The increase of p21 CIP protein level was also correlated with a decrease of hyperphosphorylated pRb as shown by western blotting using anti-phospho-pRb polyclonal antibodies. As it was previously shown that the repression of E7 protein triggered senescence of HeLa cells (Johung et al., 2007) , we analysed the expression of 18E7 and 18E6 at the transcriptional and translational levels in our cellular model. Surprisingly, in F47R-HeLa cells, and to a lesser extent in 16E6-HeLa cells, 18E6 protein levels were decreased, whereas 18E7 protein levels were not significantly modified (Figure 5c ). To address the question of this downregulation of 18E6 protein, we also examined the relative abundance of E6-encoding transcript. In cervical cancer cells, E6 and E7 are transcribed as a single bicistronic mRNA that undergoes splicing. The fulllength HPV18 E6/E7 mRNA is less abundant than the spliced HPV18 E6*I/E7 mRNA, the former and the latter being respectively the main sources for E6 and E7 polypeptides (Tang et al., 2006) . Six days after were transfected with a series of pNKA-based plasmids (pNKA, pNKA-E6, pNKA-E6 F47R, pNKA-E6 F47RDPDZ). Twenty-four hours after transfection, HeLa, C33A and H1299 cells were trypsinated and split at appropriate dilutions for protein analysis and colonyformation assay. (a) At day 2 post-transfection, cellular extracts were analysed by western blotting using anti-16E6 antibody and antiactin antibody. (b) HeLa, C33A and H1299 cells were selected with puromycin at final concentration of 0.4, 0.5, 0.6 mg/ml, respectively. After 2-3 weeks of selection, cells were fixed with 3% paraformaldehyde and stained with crystal violet.
HPV16 E6 mutant and cellular senescence T Ristriani et al transfection, total mRNAs were extracted from HeLa cells and the relative abundance of both transcripts was assessed by using real-time quantitative PCR (Figure 5d ). We observed that the spliced 18E6*I/E7 transcript was more abundant than the full-length 18E6/ E7 transcript. In comparison with control HeLa cells, we found that the level of the full-length 18E6/E7 mRNA was reduced to 1.4-fold in 16E6-HeLa cells and 3.7-fold in senescent F47R-HeLa cells. In contrast, the 18E6*I/E7 mRNA was not significantly altered in cells expressing wild type or mutant E6. The downregulation of 18E6 protein was therefore related to a depletion of E6-encoding transcript. Noteworthy enough, the downregulation of 18E6-coding transcript and protein did not appear as a specific trait of the F47R mutant, as it was also observed upon prolongated expression of wild-type 16E6 (Figures 5c and d) . The stronger effect induced by E6 F47R just appears to be correlated to its stronger expression.
The senescence phenotype is dependent on the p53 signaling pathway Next, we investigated whether the senescent phenotype observed in HeLa-expressing E6 F47R mutant was dependent on the expression level of p53. For this purpose, we used synthetic small interfering RNAs (siRNAs) to knockdown the expression of p53. HeLa cells were co-transfected with p53 siRNAs or scramble siRNAs and plasmids pNKA or pNKA-E6 F47R. After 48 h of transfection, we verified that p53 siRNAs efficiently silenced p53 expression ( Figure 6A ). The p53 protein levels were strongly reduced in HeLa cells treated with p53 siRNAs even in the presence of the E6 F47R mutant ( Figure 6A, lane 4) . In F47R cells, the expression of 18E6 protein was not significantly changed at day 2 post-transfection ( Figure 6A , lane 3), whereas it decreased strongly at day 6 post-transfection ( Figure 6A , lane 7). At day 6, treatment of F47R-expressing cells with p53 siRNA decreased the level of E6 F47R protein, while restoring 18E6 protein levels ( Figure 6A , lane 8). This indicates that the expressions of p53 and F47R proteins are mutually stabilized, and that this mutual stabilization is detrimental to 18E6 expression. At day 6 post-transfection, p53 siRNAs were able to rescue F47R-HeLa cells from cellular senescence. The cellular growth suppression ( Figure 6B ) and the SA-b-galactosidase activity ( Figure 6C ) were both inhibited in F47R cells treated with p53 siRNAs. In Figure 3 . On day 1, the cells were trypsinated and split into several 60-mm diameter dishes. (A) On day 4 post-transfection, adherent and floating cells were harvested and 70 mg of total proteins were separated on SDS-10% polyacrylamide gel and analysed by western blotting using anti-PARP1 polyclonal antibody, anti-actin antibody and anti-16E6 antibody. HeLa cells treated with staurosporine (STS) at 150 nM of final concentration for 18 h were used as a positive control of caspase-dependent apoptosis. (B) On day 2 posttransfection, HeLa cells were grown under puromycin selection. On day 6 post-transfection, the cells were fixed and stained for acidic senescence associated-b-galactosidase activity as described (Dimri et al., 1995) . Panels (a) and (b) represent cellular morphology and b-gal staining, respectively. Figure 5 Sustained induction of p53 cell signaling in senescent HeLa cells. (a) HeLa cells were transfected with a series of pNKAbased plasmids (day 0). On day 2 post-transfection, protein extracts were prepared by using lysis buffer. Forty-five mg of total proteins were separated by SDS-12% polyacrylamide gel and subjected to western blotting using the anti-p53, anti-hMDM2, anti-p21 CIP , antiactin, anti-18E6, anti-18E7 and anti-16E6 antibodies. (b) HeLa cells (35-mm diameter dishes) were co-transfected with pNKA-based plasmids (1.5 mg), luciferase p21 CIP -reporter gene vector (1 mg) and pCMV-b-galactosidase (0.5 mg) as an internal control of transfection. On day 2 post-transfection, cell lysates were evaluated for luciferase activities with a Berthold 'Centro LD 960' luminometer and luciferase activities were normalized to b-galactosidase activity. (c) HeLa cells (transfected as in a) were trypsinated, diluted, split and selected for puromycin resistance. On day 6 post-transfection, cells were harvested. Extracted proteins (45 mg) were separated by SDS-12% polyacrylamide gel (for pRb, 100 mg of proteins were separated by SDS-6% polyacrylamide gel) and analysed by western blotting using antibodies as in (a) and polyclonal phospho-pRb antibodies (*, aspecific band). (d) At day 6 post-transfection, mRNAs were extracted and reverse-transcribed into cDNA. The relative quantification of full-length 18E6/E7 cDNA and spliced E6*I/E7 cDNA was determined by real-time PCR using hPBGD cDNA as an internal control. The full-length 18E6/E7 cDNA was amplified by using E6 primers. E7 primers were designed to amplify both the full-length 18E6/E7 cDNA and the spliced E6*I/E7 cDNAs. However, as the quantity of full-length 18E6/E7 cDNA is much lower than that of spliced E6*I/E7 cDNA, E7 primers amplify preferentially the spliced E6*I/E7 cDNA. Graphic representation of the relative mRNA quantification, which was set to 1 for control HeLa cells transfected with pNKA plasmid. White bars: full-length 18 E6/E7 mRNA, gray bars: spliced 18 E6*I/E7 mRNA. Data are mean ± s.e. of three independent experiments (*Po0.05).
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T Ristriani et al conclusion, increased expression of transcriptionally active p53 appears as a pivotal event for the senescence pathway observed in F47R-HeLa cells.
Discussion
The E6 protein of high-risk genital HPV is a major viral oncoprotein, which plays a key role in cervical carcinogenesis. Here, we show that the single-point mutant E6 F47R prevents the growth and induces senescence of HPV-positive cervical cancer HeLa cells, therefore counteracting the oncogenic action of endogenous wild-type E6. This switch from an oncoprotein to a potential tumor suppressor represents a remarkable event, which deserved further mechanistic investigations. Confirming a recent report by To¨pffer et al. (2007) , we found that the E6 F47R mutant is defective for degrading the tumor suppressor p53 both in vitro (in reticulocytes extracts) and in vivo (in HPV-positive cells as well as in HPV-negative cells). Interestingly, the E6 F47R mutant retains the capacity of wild-type E6 to form a triple complex with p53 and the ubiquitin ligase E6AP. However, by contrast to E6/E6AP/p53 complexes, the F47R/E6AP/p53 complexes are deficient for p53 polyubiquitination. According to our previous published model of E6-N domain (Nomine´et al., 2006) , the F47 residue should be fully exposed to solvent. Therefore, the F47R mutation is not expected to alter the folding of the E6 protein. Nevertheless, the strong positive charge of the introduced arginine residue may generate medium-range electrostatic effects altering the catalytic activity of the F47R/E6AP/p53 complex. Structural analysis of the interaction of E6 with E6AP and p53 will be required to fully understand how the F47R mutation impairs the catalysis of p53 ubiquitination by the E6/E6AP complex.
In addition to being defective for p53 ubiquitination and degradation, the E6 F47R mutant exerts a dominant negative effect upon the p53 degradation activity of wild-type E6 both in vitro in reticulocytes extracts and in vivo in HPV-positive HeLa, CaSki and Figure 6 The senescent phenotype is dependent on p53 signaling pathway. HeLa cells (60-mm dishes) were co-transfected with pNKA or pNKA-E6 F47R plasmids and p53 small interfering RNA (siRNA) or scramble (scr) siRNA (day 0). At day 1 post-transfection, cells were trypsinated, split at appropriate dilutions for protein analysis (A), cell growth assay (B) and senescence assay (C). Starting from day 2 post-transfection until day 6, HeLa cells were grown under puromycin selection. (A) On days 2 and 6 post-transfection, cells were harvested and total proteins were separated by SDS-12% polyacrylamide gel and applied to western blotting using anti-p53 antibody, anti-16E6 antibody, anti-actin antibody and anti-18E6 antibody. (B) At day 6, cells were fixed and stained with crystal violet. (C) At day 6, cells were fixed and stained for SA-b-galactosidase activity. Panels (a) and (b) represent cellular morphology and b-gal staining, respectively.
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SiHa cells. Our data suggest that E6 F47R exerts this effect by competitive inhibition. When E6 F47R is overexpressed in high amounts, the ubiquitinationdeficient F47R/E6AP/p53 complexes must be formed predominantly over the ubiquitination-proficient E6wt/ E6AP/p53 complexes, leading to decreased degradation of p53. In addition, the ubiquitination-deficient F47R/ E6AP/p53 complexes may show an extended half-life (this is frequently observed for inactivated enzymatic complexes, which cannot release the final product), thereby enhancing the protection of p53 against degradation.
Under selection conditions ensuring its sustained expression in HeLa cells, the expression level of E6 F47R mutant was higher than that of 16E6 control ( Figures 4A and 5c) , whereas the expression level of E6 F47R was significantly decreased in the presence of p53 siRNA ( Figure 6A , lane 8). These effects can also be explained by the formation of longer-lived ubiquitinationdeficient F47R/E6AP/p53 complexes, which should stabilize not only p53, but also E6 F47R. Wild-type E6 proteins have been previously shown to be short-lived proteins prone to ubiquitination and subsequent proteasome-dependent degradation in vivo (Stewart et al., 2004) .
Upon prolonged expression of E6 F47R in HeLa cells, we also observed a downregulation of endogenous 18E6 protein levels. This raised the possibility that the upregulation of p53 might be the consequence of lower 18E6 protein expression. However, several data contradict this hypothesis. First, downregulation of endogenous 18E6 protein level was not a specific trait of the F47R mutant, as it was also observed upon expression of wildtype 16E6. The level of 18E6 downregulation just seemed to correlate with the level of overexpression of heterogeneous E6, which was higher for E6 F47R than for 16E6. Second, in our experimental conditions, the decrease of 18E6 protein level could be clearly observed only at day 6 post-transfection, whereas upregulation of p53 was fully observed already at day 2. Third, we have found that the F47R E6 mutant directly competes with wild-type E6 protein for the degradation of p53 in vitro. Therefore, direct competitive inhibition of 18E6-mediated p53 degradation is most likely to be the primary cause for F47R-mediated p53 upregulation.
The downregulation of 18E6 protein levels upon heterogeneous expression of F47R or wild-type 16E6 in HeLa cells was related to a depletion of 18E6/E7 fulllength transcript, which is the mRNA responsible for 18E6 protein expression. As for the 18E6 protein, the downregulation of 18E6/E7 full-length mRNA transcript was unambiguously observed at day 6 posttransfection, and it was more marked for the higherexpressed F47R mutant than for the lower-expressed wild-type E6. Accordingly, when the expression of E6 F47R protein was decreased upon p53 siRNA transfection ( Figure 6, lane 8) , the expression of 18E6 protein was restored.
How overexpressed HPV16 E6 (F47R or wild-type) regulates 18E6/E7 full-length transcript abundance is not known. One intriguing possibility would be a direct interaction between the overexpressed E6 F47R protein and 18E6/E7 transcript. Indeed, high-risk genital E6 is a nucleic acid-binding protein (Ristriani et al., 2000) , it copurifies in vitro with its own RNA under certain conditions (Trave´G, unpublished data), and it colocalizes with nuclear ribonucleoproteic ultrastructures and with cytoplasmic polysomes .
Earlier works had reported induction of senescence in cervical cancer cells, but generally achieved by the combined targeting of both E6 and E7 expression. For instance, the transcriptional repression of E6/E7 gene promoter through bovine papillomavirus E2 protein led to reactivation of p53 and pRb pathways and to senescence of HeLa cells (Wells et al., 2000; Horner et al., 2004) . Indeed, the repression of 18E7 alone in HeLa cells by expression of the bovine papillomavirus E2 protein induces senescence response that requires activation of endogenous pRB family members but not the p53 pathway (Johung et al., 2007) . Here, the E6 F47R-induced senescence was not associated with E7 repression and required the sustained restoration of the p53 pathway, with high p53 protein levels inducing the expression of its targets. Therefore, the F47R-induced senescence pathway appears to be rather distinct than the bovine papillomavirus E2-induced senescence pathway. It was shown earlier that overexpression of p21 CIP by itself could induce senescence in HeLa cells (Wells et al., 2000) . In E6 F47R-expressing cells, the sustained activation of p53 signaling pathway and in particular of its target, p21 CIP , may be largely involved in the induction of senescence.
Remarkably, shRNA-mediated silencing of 18E6/E7 full-length transcript in HeLa cells has also been shown, in a manner very comparable to F47R expression, to decrease by about fourfold the amounts 18E6/E7 transcript and to restore high levels in p53 expression (Butz et al., 2003) . However, the shRNA-transfected HeLa cells did not undergo senescence, but apoptosis (this result was reproduced in our laboratory). Therefore, the upregulation of p53 was necessary but might be insufficient to explain F47R-induced senescence. Whereas E6 F47R is deficient for p53 degradation, it may show other particular activities, which play a role in the observed phenotype. At present, we can just state that these additional functions essential for E6 F47R senescence in HeLa cells are not related to PDZ domain binding, as the E6 F47RDPDZ mutant performed equally well as the E6 F47R mutant. In F47R-expressing cells, the p53 protein, possibly trapped in long-lived F47R-E6AP-p53 complexes, might retain its transactivation capacity allowing cells to undergo senescence, while it might be impaired for other activities necessary for the engagement of the apoptosis program.
A thorough study of the general transcriptome and proteome modifications in HPV-positive cells expressing the E6 F47R mutant should give novel insights into E6 oncogenic properties as well as senescence activation pathways in cervical cancer cells. In addition, further structural and biochemical analysis of this mutant might improve our understanding of the molecular activities of E6.
Materials and methods
Plasmids and siRNA sequences pNKA vector (gift from IGBMC, Illkirch, France) was derived from pSG5 plasmid, allowing expression of a protein tagged with Flag at its N terminus and contained puromycinresistance gene. HPV16 E6 sequence was inserted into pXJ40, p513 and pNKA vectors, allowing expression of E6 (158 amino acids) controlled by cytomegalovirus or SV40 promoters, respectively. E6 mutants were produced by religation of cohesive PCR fragments as previously described (Zanier et al., 2007) . The GST-E6AP C843A construct was described previously (Nomine´et al., 2006) . The p53 siRNA (sens 5 0 -GGAAAUUUGCGUGUGGAGU, antisens 5 0 -ACUCCA CACGCAAAUUUCC) and scramble siRNA were purchased from Qiagen (Courtaboeuf, France).
Cells and transfection
HeLa (HPV18), CaSki (HPV16) and SiHa (HPV16) were HPV-positive cervical carcinoma cells, whereas H1299 lungcarcinoma cells (p53 defective) and C33A cervical carcinoma cells (mutated p53 in codon 273) were HPV-negative cells. Cells were maintained in Dulbecco's minimal essential medium, 10% fetal calf serum and antibiotics. HeLa, CaSki and SiHa were transfected by using JetPEI (Ozyme, SaintQuentin-en Yvelines, France), C33A by Exgen500 (Fermentas, Saint-Remy les Chevreuses, France) and H1299 by Lipofectamine (Fischer Bioblock Scientific, Illkirch, France), according to the manufacturers' instructions. HeLa cells (60-mm dishes, 90% confluent) were co-transfected with pNKA plasmids (900 ng) and siRNA (at a final concentration of 20 nM) by using Lipofectamine 2000 (Fischer Bioblock Scientific).
Protein analysis
HeLa cells (100-mm dishes) were transfected with pNKA plasmids (day 0). For PARP-1 cleavage assay, floating and adherent cells were harvested at day 4 post-transfection. At day 1, cells were trypsinated, diluted, split to several 100-mm dishes, and at day 2, cells were grown under selection by puromycin at 0.4 mg/ml. Protein extracts were prepared by using lysis buffer (100 mM Tris pH 8, 100 mM NaCl, 1% NP40, 1 mM phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, proteases inhibitors cocktail; for pRb, we added 1 mM NaF and 2 mM Na 3 VO 4 ), and cleared by centrifugation. Total protein was quantified by Bradford solution, and 45 mg of protein was separated by 12% SDS-polyacrylamide gel (for pRb, 100 mg of protein was separated by 6% SDS-polyacrylamide gel), transferred to a nitrocellulose membrane. The membrane was incubated with different antibodies: monoclonal anti-p53 antibody (Ab-6, Calbiochem, VWR, Fontenaysous-bois, France), rabbit polyclonal anti-p21 antibody (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-actin antibody (Sigma-Aldrich, Saint-Quentin Fallavier, France), anti-hMDM2 antibody (clone IF2, Zymed Laboratories, San Francisco, CA, USA), polyclonal phosphopRb antibody (Phosphoplus-Rb antibody kit, Ser 780, Ser 795, Ser 807/811, Cell Signaling Technology, Danvers, MA, USA), monoclonal anti-HPV16 E6 antibody (6F4, Euromedex, Souffelweyersheim, France), polyclonal anti-HPV18 E7 antibody (18E7C, a gift from Professor Dr H Zentgraff, DKFZ, Germany), monoclonal anti-HPV18 E6 antibody (2E9, a gift from Arbor Vita Corp., USA) and anti-PARP antibody (a gift from Dr G de Murcia, Strasbourg) and analysed by enhanced chemiluminescence (Amersham Biosciences, GE Healthcare, Orsay, France).
Immunofluorescence Cells were transfected with p513, p513-E6, p513-E6 F47R and pEGFP C3 (Clontech, Saint-Germain-en-Laye, France) plasmids. Thirty hours after transfection, cells were processed for p53 and 16E6 detection as described (Nomine´et al., 2006) .
In vivo GST pulldown C33A cells (60-mm dishes) were co-transfected with pBC (encoding GST) or pBC-E6AP C843A (encoding GST-E6AP C843A) and p513, p513-E6, p513-E6 F47R plasmids. GST pulldown was processed as described (Nomine´et al., 2006) .
mRNA quantitation by RT-PCR
The detailed protocol is provided as Supplementary Information. The relative abundance of full-length HPV18 E6/E7 mRNA (E6-encoding) and spliced HPV18 E6*I/E7 mRNA (E7-encoding) in transfected HeLa cells was assessed by using real-time quantitative PCR.
Colony-formation assay HeLa, C33A, H1299 cells (60-mm dishes) were transfected with pNKA, -E6, -E6 F47R or -E6 F47R DPDZ. After 24 h, cells were trypsinated, diluted, split, and allowed to grow during 2-3 weeks under selection with puromycin 0.4 mg/ml (HeLa), 0.5 mg/ml (C33A), 0.6 mg/ml (H1299). The colonies were fixed with 3% paraformaldehyde and stained with crystal violet. Notably, this experiment could not be performed with HPV16-positive CaSki and SiHa cells, as these cells always died during the selection process.
In situ staining of senescence-associated b-galactosidase activity Cells were fixed with 3% formaldehyde, washed with phosphate-buffered saline pH 6, 2 mM MgCl 2 , incubated for 36 h at 37 1C in SA-b-galactosidase-staining solution (1 mg/ml 5-bromo-4-chloro-3indol b-D-galactopyranoside (X-gal), 5 mM K 3 Fe[CN] 6 , 5 mM K 4 Fe[CN] 6 , 2mM MgCl 2 in phosphatebuffered saline pH 6) and then examined under bright field illumination of a microscope.
Luciferase assay
HeLa cells (35-mm dishes) were co-transfected with pNKA plasmid (1.5 mg), the firefly luciferase p21 CIP -reporter gene (1 mg) and pCMV b-galactosidase (0.5 mg) as an internal control of transfection. Forty hours later, cells were harvested and lysed with 200 ml of reporter lysis buffer (Promega, Charbonnie`res les bains, France). Twenty ml of each sample were analysed with the luciferase reporter assay using a Berthold 'Centro LD 960' luminometer. Luciferase activities of the p21 CIP -luciferase vector were normalized based on the cotransfected vector b-galactosidase activity.
In vitro p53 degradation and ubiquitination assays Detailed protocols for these assays are provided as Supplementary Information. For degradation assays, p53, E6 or F47R proteins were labeled with 35 S Met in rabbit reticulocytes lysates, and E6-mediated p53 degradation reactions were performed in the presence or absence of purified MBP-E6 or MBP-E6 F47R fusion proteins. For the ubiquitination assay, in vitro-labeled E6 and p53 proteins were allowed to react in the presence of ATP-gS, which blocked proteasome-mediated degradation, thereby enhancing the accumulation of polyubiquinated p53 molecules. The reaction was subjected to a first immunoprecipitation using anti-p53 antibodies, followed by a second immunoprecipitation using anti-ubiquitin antiserum.
